Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NIjTWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITUVI1KSzVyPUCuNVLjiIoEsfMAjVAvODFizszN MnW0NlU6PjB{OEK=
KellyCis83 NYT0PHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUezOGRwUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> M2S2[FI2QTZyMkiy
SK-N-AS NXfORW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLIc2I3UUN3ME2wMlI16oDLwsJihKkxNjB|IN88US=> NH7z[48zPTl4MEK4Ni=>
SK-N-ASCis24 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfqWWpKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN MUGyOVk3ODJ6Mh?=
U87 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7UZYFMOC13MDFOwG0> NXHMcYtSPDhiaB?= M3TzToRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NXTFc|FxOjV5NUCyO|M>
HCT116 NV73fGpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G1U|AvPS1{LkWg{txO MWC0POKhcMLi M3nSbGlEPTB;MT63N:KhyrIEoECuNlHDqM7:TR?= MmnZNlU4PDZ5NkO=
HT-29 M3;jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMlUuOi53IN88US=> M4HOdVQ5yqCqwrC= NUDae2g{UUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= NVHySpc6OjV5NE[3OlM>
Caco2 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRd4tqOC53LUKuOUDPxE1? M3fnTlQ5yqCqwrC= NFmyfolKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= MU[yOVc1Pjd4Mx?=
COLO 205 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HzTVAvPS1{LkWg{txO NW\GN|dDPDkEoHlCpC=> M1v6Z2lEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= MXmyOVc1Pjd4Mx?=
SW480 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlUuOi53IN88US=> NVXuZndGPDkEoHlCpC=> MmS1TWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP NFvBVHEzPTd2Nke2Ny=>
HEK293T MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;kNU02KM7:TR?= MWK0POKhcMLi NFjudmlKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= NFrPeHIzPTd2Nke2Ny=>
Hep3B  MmXYSpVv[3Srb36gRZN{[Xl? NGXwXFcyOCEQvF2= NV[5TIwyPDkEoHlCpC=> M1frVZJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> NGrLR5IzPTZ|M{W2OC=>
Hep3B  MmfCSpVv[3Srb36gRZN{[Xl? NIfYNWoxNjFvMUCg{txO M1e0dlI1KGh? NHq1ZWZ{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= MoPoNlU3OzN3NkS=
HEK293 M4XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? NI\4TpAzPTZyM{GyNi=>
DU145 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;nTndbUUN3ME2yMlI5yqEEsdMgNE4xPMLizszN M{jE[FI2PjB|MUKy
HCT15 NHrqdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnoUWFKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= M{DZVFI2PjB|MUKy
T47D MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\uTWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP NX33cmZDOjV4MEOxNlI>
SMMC-7721 MY\GeY5kfGmxbjDBd5NigQ>? MnXKOFAh|ryP NHjpWW41QCCq NY\KbJFCTE2VTx?= M{nHOolv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NXLDSVZROjV3NESzOlE>
MDA-MB-231 M{D6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DWelczyqCq Mo\vTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? MYSyOVQ5PjJzOR?=
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;YO|LDqGh? NEfxOXJKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= M1[ydFI2PDh4MkG5
Jurkat NWrafVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULTcGdyPzMEoHi= MknjTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? MoqwNlU1QDZ{MUm=
HeLa NFq0clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT0SJA4OsLiaB?= M4fRTGlEPTB;Mz65xsDDucLiMj6zxsDPxE1? NXTteFVXOjV2OE[yNVk>
MCF7  MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTUV2x6PS1zMECg{txO NIXIU3Q4KGR? NEfzc49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYqyOVQ4OjZzOR?=
K562 NX2yTWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrYO|LDqGh? MVnJR|UxRTBwMkpCpO69VQ>? MYmyOVI5OjZ3Mx?=
K/VP.5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj1cWJrPzMEoHi= M3;FPWlEPTB;ND65xsDPxE1? NFPmRYszPTJ6Mk[1Ny=>
SH-EP  NUDmPWNjTnWwY4Tpc44hSXO|YYm= MUeyNOKh|rypL33s Mm\BNlTDqGh? MVrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MVqyOVI3OTl6MR?=
SCC25 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0XJp[OjUEoHi= NYHaOIVCUUN3ME20N{4{yqEEsdMgNU4yOsLizszN M4rlNVI2OjJyN{K5
CAL27 NGjGfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDHVVUzPMLiaB?= MX3JR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? MUSyOVIzODd{OR?=
FaDu MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDIcHp6OjUEoHi= M1XiUmlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= NFuw[FczPTJ{MEeyPS=>
SCC25 NH3jOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70T2Y1QMLiaB?= NHjiPWNKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN M1nLVFI2OjJyN{K5
CAL27 M2fKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHufodJPDkEoHi= NYL3emw5UUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> NHHOXI0zPTJ{MEeyPS=>
FaDu MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWO0POKhcA>? MVnJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? M{X3TFI2OjJyN{K5
SCC25 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjrcWs6PzMEoHi= Ml63TWM2OD16LkSxxsDDucLiMT6xNeKh|ryP M4r0bFI2OjJyN{K5
CAL27 M4L3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DxOVczyqCq MlvBTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP M3fkPFI2OjJyN{K5
FaDu NVnkNnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jLZ|czyqCq MknCTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP M4f6ZlI2OjJyN{K5
MCF-7 NEWyOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDOc3Q1QMLiaNMg M2PhdWROW09? NGLCWI1KSzVyPUeuNuKhyrIEoECuPOKh|ryP M13xfVI2OjF4M{e4
T-47D NH\0XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0POKhcMLi M130NWROW09? MUXJR|UxRTdwN9MgxtHDqDBwN9Mg{txO MV[yOVIyPjN5OB?=
MDA-MB-231 NXHzdVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XwNFQ5yqCqwrC= NV7KWWN{TE2VTx?= NYHQXWtGUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= MVGyOVIyPjN5OB?=
DU145 M2LoPGFxd3C2b4Ppd{BCe3OjeR?= NEDIT3gyOC1zMECg{txO NHLtbG05KGh? M1PkNmROW09? MVLpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? MX6yOVE1QTZ6MR?=
DU145 stem-like M2jafGFxd3C2b4Ppd{BCe3OjeR?= NXr2OYVuOTBvMUCwJO69VQ>? MX[4JIg> NX3y[4ttTE2VTx?= NYfSPJVQcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWOyOVE1QTZ6MR?=
DU145 M4GyWmZ2dmO2aX;uJGF{e2G7 NICzRZYyOC1zMECg{txO M1vKXVIhcA>? M{HPXWROW09? NEPJVJVqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVn5WldrOjVzNEm2PFE>
DU145 stem-like MlztSpVv[3Srb36gRZN{[Xl? MVWxNE0yODBizszN MXmyJIg> NFfhTnRFVVOR MkLsbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn\jNlUyPDl4OEG=
UW228-3 NFnrZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwXGsxNjBzLUOwNEDPxE1? MnPuOFghcA>? Mn;zSG1UVw>? MXLJR|UxRTBwOUpCpO69VQ>? MXyyOVEyQTF6NR?=
NSCs NWnzWlR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rkdFAvODFvM{CwJO69VQ>? MUS0PEBp NH\yb25FVVOR NFrsXVlKSzVyPUCuN{0{yqEQvF2= Mo[1NlUyOTlzOEW=
MKL-1  NUXvNnplTnWwY4Tpc44hSXO|YYm= NXnBNGZqOTBvMUCwNEBvVQ>? MoXWOEBl MXzpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? MWCyOVEyPjd3NB?=
MCF7 EV M170[mZ2dmO2aX;uJGF{e2G7 M2nsNlExNTFyMDFOwG0> NVSx[Vd4OuLCiXi= MWfpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MV:yOVA5QDJyMx?=
MCF 7BMI1 M3LDfGZ2dmO2aX;uJGF{e2G7 MXexNE0yODBizszN MUOy5qCKcA>? M2PH[Ylv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NYP2R4FPOjVyOEiyNFM>
MCF7 EV NIjSSWNHfW6ldHnvckBCe3OjeR?= Mme1NVAuOTByIN88US=> NInRNZcz6oDLaB?= MX3FWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= Ml3VNlUxQDh{MEO=
MCF7 BMI1 NWTyU2tYTnWwY4Tpc44hSXO|YYm= Ml:4NVAuOTByIN88US=> NUWzNodZOuLCiXi= M{S3bWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NYfETldFOjVyOEiyNFM>
HepG2 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrQRnNoTE2VT9Mg MmrVTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= MViyOVA4QDNzMR?=
MOLT-3 NVTsbZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;EUXNQyqB? M1nwcGlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MmHHNlUxPzh|MUG=
HT1080 M1PFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjKNU0yODBizszN MUe0M|I1NzR6IHi= M3nD[mROW00EoB?= MXjpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NFntTFYzPTB5OEC2OC=>
HT1080 M4L1U2Z2dmO2aX;uJGF{e2G7 M4m3TFAvODByMT2xNFAh|ryP MYqxMVI1KGh? MYrEUXNQyqB? M1m0T4lv\HWlZYOgdE1xPTNqc3XyNVUqKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NWPkfGo5OjVyN{iwOlQ>
HT1080 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7DcmlWOC5yMECxMVExOCEQvF2= MlHBNlQhcA>? MW\EUXNQyqB? MmDOZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= MVqyOVA4QDB4NB?=
HD-MY-Z NFfUOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXKWo1WOjRxNEivO|IhcA>? M2fz[WlEPTExvK6xNFAh|ryP NFruSFIzPTB2OEKzOi=>
DOHH-2 NH;hO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrzNlQhcA>? MVzJR|Ux97zgMUCwJO69VQ>? M1;YUlI2ODR6MkO2
DOHH-2 NVnPNog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrKdVg1QCCq NYPRdZhjUUN3ME2xPU46yqEQvF2= MoLoNlUxPDh{M{[=
DOHH-2 NWPsephXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3TRZJqPzJiaB?= MoHpTWM2OD13wrFOwG0> M1PCO|I2ODR6MkO2
REH M1HvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXzWXpYOjRiaB?= MmO2TWM2OD1yLkCyO:Kh|ryP M3ziOlI2ODR6MkO2
REH NI\SdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0PEBp M3u4V2lEPTB;MD6wNVTDqM7:TR?= MUmyOVA1QDJ|Nh?=
REH NI\HdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu3NkBp M{HYPGlEPTB;MD6wNVXDqM7:TR?= M4fEdlI2ODR6MkO2
HH M2TxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fOVFI1KGh? MXHJR|UxRTFyND63xsDPxE1? NUe4T|E{OjVyNEiyN|Y>
HH NEmwbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrqb2I1QCCq NH[wTHVKSzVyPUS4MlbDqM7:TR?= NXrJO48{OjVyNEiyN|Y>
HH NVez[WtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLMO|IhcA>? M2C5UmlEPTB;MUSuO:Kh|ryP Mn\vNlUxPDh{M{[=
HuT-78 NVPpeFdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TXVFI1KGh? NGnIVZZKSzVyPUmuN:Kh|ryP MVOyOVA1QDJ|Nh?=
HuT-78 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH2OFghcA>? M4rMZWlEPTB;ND6zxsDPxE1? NYi1UG5HOjVyNEiyN|Y>
HuT-78 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsO|IhcA>? Mn:xTWM2OD12LkNCpO69VQ>? NGCyTVYzPTB2OEKzOi=>
OPM-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwdYpiOjRiaB?= M1:2SWlEPTB;MkSuNeKh|ryP M4L0VlI2ODR6MkO2
OPM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITJVo01QCCq NGTSR|VKSzVyPUVCpO69VQ>? Mn\oNlUxPDh{M{[=
OPM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGniUZk4OiCq MYTJR|UxRTFwM9Mg{txO NEDSWJMzPTB2OEKzOi=>
RPMI-8226 M13US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH4NlQhcA>? MVLJR|UxRTFyNj62xsDPxE1? NXTJU5VTOjVyNEiyN|Y>
RPMI-8226 MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\HfVQ5KGh? MVvJR|UxRTlzLkJCpO69VQ>? NIm1R4szPTB2OEKzOi=>
RPMI-8226 M4rFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3NkBp M1u1dWlEPTB;MUSuPeKh|ryP NXPCc2VwOjVyNEiyN|Y>
U-266 NVPOSVVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q5UlI1KGh? MWrJR|UxRTh4LkNCpO69VQ>? MnXWNlUxPDh{M{[=
U-266 M4fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXMOFghcA>? M{PIWGlEPTB;NkiuOOKh|ryP MWKyOVA1QDJ|Nh?=
U-266 NXjKcIVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDNWV1PzJiaB?= NF7w[IVKSzVyPUK3MlTDqM7:TR?= M1rNelI2ODR6MkO2
Kelly NF7tWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMNE0yOCEQvF2= MYS3NuKhcA>? M33ZZmlEPTB;MT61NVjDqM7:TR?= Ml7qNlUxODh7MEC=
SH-SY5Y  NFfG[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPCVJoxNTFyIN88US=> MVK3NuKhcA>? M{fGdGlEPTB;MD63OVTDqM7:TdMg NXvyRXVpOjVyMEi5NFA>
SK-N-AS M1rRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17T[FAuOTBizszN NF2ySWU4OsLiaB?= NIHyd25KSzVyPUGuO|EzyqEQvF5CpC=> NYrG[mduOjVyMEi5NFA>
SK-N-DZ NGLxNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVExKM7:TR?= MY[3NuKhcA>? NIDWfWlKSzVyPUWuOFg2yqEQvF2= NWHZeppyOjVyMEi5NFA>
HepG2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xOFjDqGh? MUfEUXNQyqB? MULJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP MnjCNlQ6QTZzM{[=
A549 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLsOFjDqGh? NUn6U5ZLTE2VT9Mg MlizTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MoHzNlQ6QTZzM{[=
MCF7 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nNVVQ5yqCq Mor5SG1UV8Li M1r3dWlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN M1\rV|I1QTl4MUO2
HL-60  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPyfFdTPzMEoHi= NVPkOJRXUUN3ME2wMlEz6oDHzszN NYrFc5lmOjR7OUOwNVQ>
HL-60[R] NYHveYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\DT|czyqCq MoHOTWM2OD1|LkGy5qCG|ryP M{PEOlI1QTl|MEG0
MIAPACA NWLDOpZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[yW2dKPTB;MT6zJOKyKDBwMEOg{txO M1jRN|I1QTV|OEKx
MCF-7 NHnmU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvHTVUxRTBwMkWgxtEhOC5zIN88US=> MW[yOFk2Ozh{MR?=
HeLa MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nvN2dKPTB;MD62OEDDuSByLkSg{txO NUC5fZFPOjR7NUO4NlE>
MO59K  M2i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfKOFA4KGR? MX\JR|UxRTBwMUhihKXPxE1? Ml\ENlQ6PTN3NkG=
MO59J NFXlbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXW3JIQ> MoTSTWM2OD1yLkJihKXPxE1? MkTzNlQ6PTN3NkG=
ME 180 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfZOFjDqGkEoB?= NEjQVY9KSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= MXeyOFk2OzB{Nx?=
MCF-7 M{XwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCzeG5KPDkEoHlCpC=> NY\pUXh1UUN3ME2yN{46KMLzIECuN-KBjc7:TR?= M2HjUVI1QTV|MEK3
HeLa NEXhOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm0POKhcMLi NWLSbZpKUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MofGNlQ6PTNyMke=
MDA-MB-453 NWHDV2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PxZVQ5yqCqwrC= NY\ZUIRSUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= NWjGNIVMOjR7NUOwNlc>
MDA-MB-231 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;hOFjDqGkEoB?= M{PqPGlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= M1K5RVI1QTV|MEK3
PC-3 NXPldHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnWUIc2PDkEoHlCpC=> M{KyWWlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP MmrNNlQ6PTNyMke=
HT-29 M4\vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6WpA1QMLiaNMg M{jkRmlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= M17hV|I1QTV|MEK3
BGC-823 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrNWok1QMLiaNMg NInKeXJKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= M{HqbVI1Pzl|OEe3
HeLa NXzLS3h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi0POKhcMLi M1nuXWlEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> NGHG[lQzPDd7M{i3Oy=>
A549 NFnzfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXNOFjDqGkEoB?= MlfPTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= M2jIWlI1Pzl|OEe3
HK-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi0POKhcMLi Mlr3TWM2OD17LkG3JOKyKDFwNUlihKXPxE1? MWCyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03669783 Not yet recruiting Childhood Renal Tumor Assistance Publique Hopitaux De Marseille January 1 2019 Phase 3
NCT03742115 Not yet recruiting Hemophagocytic Lymphohistiocytosis Beijing Friendship Hospital December 1 2018 Phase 3
NCT03711305 Not yet recruiting Extensive-stage Small Cell Lung Cancer Jiangsu HengRui Medicine Co. Ltd. December 2018 Phase 3
NCT03579927 Not yet recruiting CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 2018 Phase 1|Phase 2
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID